Safety and efficacy of SARS‐Cov2 neutralizing monoclonal antibodies after stem cell transplant or CAR‐T cell infusion.

MLA

Metafuni, Elisabetta, et al. “Safety and Efficacy of SARS‐Cov2 Neutralizing Monoclonal Antibodies after Stem Cell Transplant or CAR‐T Cell Infusion.” Hematological Oncology, vol. 41, no. 3, Aug. 2023, pp. 563–66. EBSCOhost, https://doi.org/10.1002/hon.3119.

APA

Metafuni, E., Cingolani, A., Fantoni, M., Chiusolo, P., Giammarco, S., Sorà, F., Galli, E., Hohaus, S., D’Alò, F., Bellesi, S., Maiolo, E., Alma, E., Laurenti, L., Innocenti, I., Autore, F., Limongiello, M. A., Santangelo, R., Marchetti, S., Ricci, R., & Sica, S. (2023). Safety and efficacy of SARS‐Cov2 neutralizing monoclonal antibodies after stem cell transplant or CAR‐T cell infusion. Hematological Oncology, 41(3), 563–566. https://doi.org/10.1002/hon.3119

Chicago

Metafuni, Elisabetta, Antonella Cingolani, Massimo Fantoni, Patrizia Chiusolo, Sabrina Giammarco, Federica Sorà, Eugenio Galli, et al. 2023. “Safety and Efficacy of SARS‐Cov2 Neutralizing Monoclonal Antibodies after Stem Cell Transplant or CAR‐T Cell Infusion.” Hematological Oncology 41 (3): 563–66. doi:10.1002/hon.3119.